{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:27:26Z","timestamp":1782390446209,"version":"3.54.5"},"reference-count":64,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"American Cancer Society Institutional Research Grant"},{"name":"VA Merit Review Award Program"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA141426, R21 CA179017, R01 AR059679"],"award-info":[{"award-number":["R21 CA141426, R21 CA179017, R01 AR059679"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Cell. Physiol."],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1002\/jcp.25351","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T04:33:29Z","timestamp":1456374809000},"page":"2374-2379","source":"Crossref","is-referenced-by-count":24,"title":["Current Controversies in the Management of Myeloma Bone Disease"],"prefix":"10.1002","volume":"231","author":[{"given":"Rebecca","family":"Silbermann","sequence":"first","affiliation":[{"name":"Department of Medicine; Hematology\/Oncology; Indiana University; Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garson David","family":"Roodman","sequence":"additional","affiliation":[{"name":"Department of Medicine; Hematology\/Oncology; Indiana University; Indianapolis Indiana"},{"name":"Richard L. Roudebush VA Medical Center; Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"10.1002\/jcp.25351-BIB0001|jcp25351-cit-0001","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0609.1996.tb01395.x","article-title":"Assessment of bone involvement in patients with multiple myeloma using bone densitometry","volume":"57","author":"Abildgaard","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1002\/jcp.25351-BIB0002|jcp25351-cit-0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1002\/jcp.25351-BIB0003|jcp25351-cit-0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1002\/jcp.25351-BIB0004|jcp25351-cit-0004","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1002\/jcp.25351-BIB0005|jcp25351-cit-0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","article-title":"Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function","volume":"37","author":"Berenson","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jcp.25351-BIB0006|jcp25351-cit-0006","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1002\/jcp.25351-BIB0007|jcp25351-cit-0007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after 1 year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/jcp.25351-BIB0008|jcp25351-cit-0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1002\/jcp.25351-BIB0009|jcp25351-cit-0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0010|jcp25351-cit-0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone"},{"key":"10.1002\/jcp.25351-BIB0011|jcp25351-cit-0011","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1002\/jcp.25351-BIB0012|jcp25351-cit-0012","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/jcp.25351-BIB0013|jcp25351-cit-0013","doi-asserted-by":"crossref","first-page":"21352","DOI":"10.1074\/jbc.M111663200","article-title":"Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix","volume":"277","author":"Dallas","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1002\/jcp.25351-BIB0014|jcp25351-cit-0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1759720X13477714","article-title":"Bisphosphonate drug holiday: Who, when and how long","volume":"5","author":"Diab","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1002\/jcp.25351-BIB0015|jcp25351-cit-0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/jcp.25351-BIB0016|jcp25351-cit-0016","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0017|jcp25351-cit-0017","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jbmr.2387","article-title":"Unveiling skeletal fragility in patients diagnosed with MGUS: No longer a condition of undetermined significance","volume":"29","author":"Drake","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1002\/jcp.25351-BIB0018|jcp25351-cit-0018","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/jcp.25351-BIB0019|jcp25351-cit-0019","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1002\/jcp.25351-BIB0020|jcp25351-cit-0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jcp.25351-BIB0021|jcp25351-cit-0021","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/jcp.25351-BIB0022|jcp25351-cit-0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/bonekey.2012.135","article-title":"Mechanisms of multiple myeloma bone disease","volume":"1","author":"Galson","year":"2012","journal-title":"Bonekey Rep"},{"key":"10.1002\/jcp.25351-BIB0023|jcp25351-cit-0023","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garcia-Sanz","year":"2015","journal-title":"Haematologica"},{"key":"10.1002\/jcp.25351-BIB0024|jcp25351-cit-0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1002\/jcp.25351-BIB0025|jcp25351-cit-0025","doi-asserted-by":"crossref","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Harousseau","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1002\/jcp.25351-BIB0026|jcp25351-cit-0026","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1002\/jcp.25351-BIB0027|jcp25351-cit-0027","unstructured":"2015 http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/multiple-myeloma#1"},{"key":"10.1002\/jcp.25351-BIB0028|jcp25351-cit-0028","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1002\/jcp.25351-BIB0029|jcp25351-cit-0029","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","article-title":"Interpretation and use of FRAX in clinical practice","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1002\/jcp.25351-BIB0030|jcp25351-cit-0030","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1002\/jcp.25351-BIB0031|jcp25351-cit-0031","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007a","journal-title":"N Engl J Med"},{"key":"10.1002\/jcp.25351-BIB0032|jcp25351-cit-0032","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007b","journal-title":"J Clin Oncol"},{"key":"10.1002\/jcp.25351-BIB0033|jcp25351-cit-0033","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/jcp.25351-BIB0034|jcp25351-cit-0034","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/jcp.25351-BIB0035|jcp25351-cit-0035","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/jcp.25351-BIB0036|jcp25351-cit-0036","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: A population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1002\/jcp.25351-BIB0037|jcp25351-cit-0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1002\/jcp.25351-BIB0038|jcp25351-cit-0038","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: A network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/jcp.25351-BIB0039|jcp25351-cit-0039","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1002\/jcp.25351-BIB0040|jcp25351-cit-0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): Secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1002\/jcp.25351-BIB0041|jcp25351-cit-0041","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0042|jcp25351-cit-0042","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1002\/jcp.25351-BIB0043|jcp25351-cit-0043","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-006-0184-3","article-title":"PET\/CT and MR imaging in myeloma","volume":"36","author":"Mulligan","year":"2007","journal-title":"Skeletal Radiol"},{"key":"10.1002\/jcp.25351-BIB0044|jcp25351-cit-0044","article-title":"Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: Results of the Z-MARK study","author":"Noopur","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1002\/jcp.25351-BIB0045|jcp25351-cit-0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group Consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1002\/jcp.25351-BIB0046|jcp25351-cit-0046","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0047|jcp25351-cit-0047","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1002\/jcp.25351-BIB0048|jcp25351-cit-0048","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"10.1002\/jcp.25351-BIB0049|jcp25351-cit-0049","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1002\/jcp.25351-BIB0050|jcp25351-cit-0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12346","article-title":"Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: A systematic review","volume":"162","author":"Regelink","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1002\/jcp.25351-BIB0051|jcp25351-cit-0051","first-page":"64","volume-title":"Treatment of multiple myeloma and related disorders","author":"Roodman","year":"2009"},{"key":"10.1002\/jcp.25351-BIB0052|jcp25351-cit-0052","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/jcp.25351-BIB0053|jcp25351-cit-0053","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1002\/jcp.25351-BIB0054|jcp25351-cit-0054","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1002\/jcp.25351-BIB0055|jcp25351-cit-0055","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/jcp.25351-BIB0056|jcp25351-cit-0056","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1002\/jcp.25351-BIB0057|jcp25351-cit-0057","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/jcp.25351-BIB0058|jcp25351-cit-0058","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1002\/jcp.25351-BIB0059|jcp25351-cit-0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1002\/jcp.25351-BIB0060|jcp25351-cit-0060","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1002\/jcp.25351-BIB0061|jcp25351-cit-0061","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1002\/jcp.25351-BIB0062|jcp25351-cit-0062","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-10-435750","article-title":"Optimal use of bisphosphonates in patients with multiple myeloma","author":"Terpos","year":"2013","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0063|jcp25351-cit-0063","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"10.1002\/jcp.25351-BIB0064|jcp25351-cit-0064","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Journal of Cellular Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcp.25351","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcp.25351","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcp.25351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T15:56:06Z","timestamp":1718380566000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcp.25351"}},"subtitle":["MANAGEMENT OF MYELOMA BONE DISEASE"],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/jcp.25351","archive":["Portico"],"relation":{},"ISSN":["0021-9541"],"issn-type":[{"value":"0021-9541","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}